专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060246197A1 Process and composition of preparing granular sucralose for emulating table sugar 审中-公开
公开(公告)号：US20060246197A1
公开(公告)日：2006-11-02
申请号：US11296580
申请日：2005-12-07
申请人： Rajesh Kshirsagar , Mayank Joshi , Amresh Kumar
发明人： Rajesh Kshirsagar , Mayank Joshi , Amresh Kumar
IPC分类号： A23L1/236
CPC分类号： A23L27/37 , A23V2002/00 , A23V2200/132 , A23V2250/264
摘要： A low-calorie solid, pourable composition for emulating sugar, the composition comprising an intense sweetener and at least one low-calorie bulking agent selected from maltodextrin, magnesium oxide, magnesium carbonate, calcium stearate, colloidal silicon dioxide and starch or combinations thereof, and a process for the preparation of said composition.

2. 发明申请

US20090220663A1 Process and composition of preparing granular sucralose for emulating table sugar 审中-公开
标题翻译：制备颗粒状三氯蔗糖的工艺和组成，用于模拟桌面糖
公开(公告)号：US20090220663A1
公开(公告)日：2009-09-03
申请号：US10558514
申请日：2005-10-10
申请人： Rajesh Kshirsagar , Mayank Joshi , Amresh Kumar
发明人： Rajesh Kshirsagar , Mayank Joshi , Amresh Kumar
IPC分类号： A23L1/236 , A23L1/0522 , A23P1/02
CPC分类号： A23L27/37 , A23V2002/00 , A23V2200/132 , A23V2250/264
摘要： A low-calorie solid, pourable composition for emulating sugar, the composition comprising an intense sweetener and at least one low-calorie bulking agent selected from maltodextrin, magnesium oxide, magnesium carbonate, calcium stearate, colloidal silicon dioxide and starch or combinations thereof, and a process for the preparation of said composition.
摘要翻译：一种用于模拟糖的低热量固体可倾倒组合物，该组合物包含强甜味剂和至少一种选自麦芽糖糊精，氧化镁，碳酸镁，硬脂酸钙，胶体二氧化硅和淀粉或其组合的低热量填充剂，以及一种制备所述组合物的方法。

3. 发明申请

US20060110454A1 Extended release formulation of pramipexole dihydrochloride 审中-公开
标题翻译：普拉克索二盐酸盐的延长释放制剂
公开(公告)号：US20060110454A1
公开(公告)日：2006-05-25
申请号：US11260066
申请日：2005-10-27
申请人： Rajesh Kshirsagar , Mayank Joshi , Amresh Kumar
发明人： Rajesh Kshirsagar , Mayank Joshi , Amresh Kumar
IPC分类号： A61K31/428 , A61K9/22
CPC分类号： A61K9/5078 , A61K9/2081 , A61K9/5047 , A61K31/428
摘要： An extended release composition of Pramipexole or a pharmaceutical acceptable salt thereof, wherein the active agent is coated on a non pareil inert core, the drug loaded core is further coated with a polymeric layer which enables the release of the active agent over an extended period and optionally the extended release pellets being further blended with suitable excipients and compressed into a multi unit tablet and processes for the preparation of the said composition.
摘要翻译：普拉克索或其药学上可接受的盐的延长释放组合物，其中所述活性剂涂覆在非帕里尔惰性核心上，所述药物负载核心还进一步涂覆聚合物层，所述聚合物层能够在长时间内释放活性剂，任选地，延长释放丸粒进一步与合适的赋形剂混合并压制成多单位片剂并制备所述组合物。

4. 发明授权

US07858122B2 Extended release formulation of levetiracetam 有权
标题翻译：左乙拉西坦的延长释放制剂
公开(公告)号：US07858122B2
公开(公告)日：2010-12-28
申请号：US11215947
申请日：2005-08-31
申请人： Rajesh Kshirsagar , Mayank Joshi , Yogesh Raichandani
发明人： Rajesh Kshirsagar , Mayank Joshi , Yogesh Raichandani
IPC分类号： A01N43/36 , A61K31/40 , A61K9/22
CPC分类号： A61K31/4015 , A61K9/1635 , A61K9/2054 , A61K9/2077 , A61K9/2866
摘要： An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.
摘要翻译：延长释放的左乙拉西坦药物组合物，每日一次剂量方案及其制备方法。左乙拉西坦的延长释放片剂包含左乙拉西坦和水分散速率控制聚合物的核心，并且片芯任选地功能性涂覆，包括水不可分散和/或水分散性聚合物的组合。它通过消除患者血浆中药物浓度的波谷和峰值，在二十四小时内提供延长的治疗有效血浆水平，减少神经精神不良事件的发生率，其包括向有需要的患者口服延长释放片剂其提供左乙拉西坦的血浆血浆水平高达约8至16小时。核心通过湿法造粒，干法制粒或直接压片制备，并且任选地，片芯包被在涂布盘或流化床系统中。

5. 发明授权

US07807195B2 Extended release formulation of venlafaxine hydrochloride 有权
标题翻译：盐酸文拉法辛缓释制剂
公开(公告)号：US07807195B2
公开(公告)日：2010-10-05
申请号：US11031266
申请日：2005-01-07
申请人： Sampad Bhattacharya , Rajesh Kshirsagar , Mayank Joshi , Sandeep Pandita
发明人： Sampad Bhattacharya , Rajesh Kshirsagar , Mayank Joshi , Sandeep Pandita
IPC分类号： A61K9/64 , A61K9/52 , A61K9/20
CPC分类号： A61K9/4808 , A61K9/2866 , A61K31/137
摘要： The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard gelatin capsules.
摘要翻译：本发明涉及包含盐酸文拉法辛和药学上可接受的赋形剂的每日一次药物制剂。更具体地说，本发明涉及一种微胶囊形式的延缓释放组合物，其被并入硬明胶胶囊中。

6. 发明申请

US20050169985A1 Extended release formulation of venlafaxine hydrochloride 有权
标题翻译：盐酸文拉法辛缓释制剂
公开(公告)号：US20050169985A1
公开(公告)日：2005-08-04
申请号：US11031266
申请日：2005-01-07
申请人： Sampad Bhattacharya , Rajesh Kshirsagar , Mayank Joshi , Sandeep Pandita
发明人： Sampad Bhattacharya , Rajesh Kshirsagar , Mayank Joshi , Sandeep Pandita
IPC分类号： A61K9/20 , A61K9/28 , A61K9/48 , A61K31/137 , A61K9/64 , A61K9/52
CPC分类号： A61K9/4808 , A61K9/2866 , A61K31/137
摘要： The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard gelatin capsules.
摘要翻译：本发明涉及包含盐酸文拉法辛和药学上可接受的赋形剂的每日一次药物制剂。更具体地说，本发明涉及一种微胶囊形式的延缓释放组合物，其被并入硬明胶胶囊中。

7. 发明申请

US20110064807A1 EXTENDED RELEASE FORMULATION OF LEVETIRACETAM 审中-公开
标题翻译：延长释放配方的利多卡因
公开(公告)号：US20110064807A1
公开(公告)日：2011-03-17
申请号：US12942585
申请日：2010-11-09
申请人： Rajesh Kshirsagar , Mayank Joshi , Yogesh Raichandani
发明人： Rajesh Kshirsagar , Mayank Joshi , Yogesh Raichandani
IPC分类号： A61K9/28 , A61K31/4015 , A61K9/36 , A61P25/08
CPC分类号： A61K31/4015 , A61K9/1635 , A61K9/2054 , A61K9/2077 , A61K9/2866
摘要： An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.
摘要翻译：延长释放的左乙拉西坦药物组合物，每日一次剂量方案及其制备方法。左乙拉西坦的延长释放片剂包含左乙拉西坦和水分散速率控制聚合物的核心，并且片芯任选地功能性涂覆，包括水不可分散和/或水分散性聚合物的组合。它通过消除患者血浆中药物浓度的波谷和峰值，在二十四小时内提供延长的治疗有效血浆水平，减少神经精神不良事件的发生率，其包括向有需要的患者口服延长释放片剂其提供左乙拉西坦的血浆血浆水平高达约8至16小时。核心通过湿法造粒，干法制粒或直接压片制备，并且任选地，片芯包被在涂布盘或流化床系统中。

8. 发明申请

US20060165796A1 Extended release formulation of levetiracetam 有权
标题翻译：左乙拉西坦的延长释放制剂
公开(公告)号：US20060165796A1
公开(公告)日：2006-07-27
申请号：US11215947
申请日：2005-08-31
申请人： Rajesh Kshirsagar , Mayank Joshi , Yogesh Raichandani
发明人： Rajesh Kshirsagar , Mayank Joshi , Yogesh Raichandani
IPC分类号： A61K31/4015 , A61K9/24
CPC分类号： A61K31/4015 , A61K9/1635 , A61K9/2054 , A61K9/2077 , A61K9/2866
摘要： An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.
摘要翻译：延长释放的左乙拉西坦药物组合物，每日一次剂量方案及其制备方法。左乙拉西坦的延长释放片剂包含左乙拉西坦和水分散速率控制聚合物的核心，并且片芯任选地功能性涂覆，包括水不可分散和/或水分散性聚合物的组合。它通过消除患者血浆中药物浓度的波谷和峰值，在二十四小时内提供延长的治疗有效血浆水平，减少神经精神不良事件的发生率，其包括向有需要的患者口服延长释放片剂其提供左乙拉西坦的血浆血浆水平高达约8至16小时。核心通过湿法造粒，干法制粒或直接压片制备，并且任选地，片芯包被在涂布盘或流化床系统中。

9. 发明申请

US20110064808A1 EXTENDED RELEASE FORMULATION OF LEVETIRACETAM 审中-公开
标题翻译：延长释放配方的利多卡因
公开(公告)号：US20110064808A1
公开(公告)日：2011-03-17
申请号：US12944936
申请日：2010-11-12
申请人： Rajesh Kshirsagar , Ashwin Rao , Nilesh Malaviya , Kaustubh Jinturkar
发明人： Rajesh Kshirsagar , Ashwin Rao , Nilesh Malaviya , Kaustubh Jinturkar
IPC分类号： A61K9/28 , A61K31/4015 , A61K9/36 , A61P25/08
CPC分类号： A61K31/4015 , A61K9/1635 , A61K9/2054 , A61K9/2077 , A61K9/2866
摘要： The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.
摘要翻译：本发明涉及左乙拉西坦的延长释放药物组合物及其制备方法。左乙拉西坦的延长释放片剂具有包含左乙拉西坦和水分散速率控制聚合物的核心，并且片芯任选地功能性涂覆，包含水不可分散和/或水分散性聚合物的组合。它通过消除患者血浆中药物浓度的波谷和峰值，在二十四小时内提供延长的治疗有效血浆水平，减少神经精神不良事件的发生率。该组合物也没有食物作用。

10. 发明申请

US20110318413A1 EXTENDED RELEASE FORMULATIONS CONTAINING DARIFENACIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF 审中-公开
标题翻译：含有生物素化合物或其药学上可接受的盐的延长释放配方
公开(公告)号：US20110318413A1
公开(公告)日：2011-12-29
申请号：US13166446
申请日：2011-06-22
申请人： Rajesh Kshirsagar , Ganesh Shinde , Pravin Kamble
发明人： Rajesh Kshirsagar , Ganesh Shinde , Pravin Kamble
IPC分类号： A61K31/4025 , A61K9/28 , A61K9/36 , A61K9/00
CPC分类号： A61K31/4025 , A61K9/2018 , A61K9/2866
摘要： The present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials; wherein said formulation provides controlled release of the darifenacin over the period of 24 hours. The present invention further relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof, wherein darifenacin is incorporated in a matrix comprising one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials.
摘要翻译：本发明涉及一种延长释放制剂，其包含达曲他宁或其药学上可接受的盐和一种或多种释放控制疏水性材料，任选地涂覆有一种或多种释放控制疏水性材料和一种或多种释放控制亲水性材料的组合; 其中所述制剂在24小时内提供达赖芬那新的受控释放。本发明还涉及包含达赖芬那定或其药学上可接受的盐的延长释放制剂，其中将达曲他宁并入包含一种或多种释放控制疏水性材料和一种或多种释放控制亲水性材料的基质中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式